Development of early life gut resistome and mobilome across gestational ages and microbiota-modifying treatments
Background - Gestational age (GA) and associated level of gastrointestinal tract maturation are major factors driving the initial gut microbiota composition in preterm infants. Besides, compared to term infants, premature infants often receive antibiotics to treat infections and probiotics to restor...
Published in: | eBioMedicine |
---|---|
Main Authors: | , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Elsevier
2023
|
Subjects: | |
Online Access: | https://hdl.handle.net/10037/30066 https://doi.org/10.1016/j.ebiom.2023.104613 |
id |
ftunivtroemsoe:oai:munin.uit.no:10037/30066 |
---|---|
record_format |
openpolar |
spelling |
ftunivtroemsoe:oai:munin.uit.no:10037/30066 2023-09-05T13:21:57+02:00 Development of early life gut resistome and mobilome across gestational ages and microbiota-modifying treatments Bargheet, Ahmed Klingenberg, Claus Andreas Esaiassen, Eirin Hjerde, Erik Cavanagh, Jorunn Pauline Bengtsson-Palme, Johan Pettersen, Veronika K. 2023-05-13 https://hdl.handle.net/10037/30066 https://doi.org/10.1016/j.ebiom.2023.104613 eng eng Elsevier EBioMedicine Sigma2: NN8021K Tromsø forskningsstiftelse: 18_CANS_AS Bargheet, Klingenberg, Esaiassen, Hjerde, Cavanagh, Bengtsson-Palme, Pettersen. Development of early life gut resistome and mobilome across gestational ages and microbiota-modifying treatments. EBioMedicine. 2023;92 FRIDAID 2151471 doi:10.1016/j.ebiom.2023.104613 2352-3964 https://hdl.handle.net/10037/30066 Attribution 4.0 International (CC BY 4.0) openAccess Copyright 2023 The Author(s) https://creativecommons.org/licenses/by/4.0 Journal article Tidsskriftartikkel Peer reviewed publishedVersion 2023 ftunivtroemsoe https://doi.org/10.1016/j.ebiom.2023.104613 2023-08-23T23:07:13Z Background - Gestational age (GA) and associated level of gastrointestinal tract maturation are major factors driving the initial gut microbiota composition in preterm infants. Besides, compared to term infants, premature infants often receive antibiotics to treat infections and probiotics to restore optimal gut microbiota. How GA, antibiotics, and probiotics modulate the microbiota’s core characteristics, gut resistome and mobilome, remains nascent. Methods - We analysed metagenomic data from a longitudinal observational study in six Norwegian neonatal intensive care units to describe the bacterial microbiota of infants of varying GA and receiving different treatments. The cohort consisted of probiotic-supplemented and antibiotic-exposed extremely preterm infants (n = 29), antibiotic-exposed very preterm (n = 25), antibiotic-unexposed very preterm (n = 8), and antibiotic-unexposed full-term (n = 10) infants. The stool samples were collected on days of life 7, 28, 120, and 365, and DNA extraction was followed by shotgun metagenome sequencing and bioinformatical analysis. Findings - The top predictors of microbiota maturation were hospitalisation length and GA. Probiotic administration rendered the gut microbiota and resistome of extremely preterm infants more alike to term infants on day 7 and ameliorated GA-driven loss of microbiota interconnectivity and stability. GA, hospitalisation, and both microbiota-modifying treatments (antibiotics and probiotics) contributed to an elevated carriage of mobile genetic elements in preterm infants compared to term controls. Finally, Escherichia coli was associated with the highest number of antibiotic-resistance genes, followed by Klebsiella pneumoniae and Klebsiella aerogenes. Interpretation - Prolonged hospitalisation, antibiotics, and probiotic intervention contribute to dynamic alterations in resistome and mobilome, gut microbiota characteristics relevant to infection risk. Funding - Odd-Berg Group, Northern Norway Regional Health Authority. Article in Journal/Newspaper Northern Norway University of Tromsø: Munin Open Research Archive Norway eBioMedicine 92 104613 |
institution |
Open Polar |
collection |
University of Tromsø: Munin Open Research Archive |
op_collection_id |
ftunivtroemsoe |
language |
English |
description |
Background - Gestational age (GA) and associated level of gastrointestinal tract maturation are major factors driving the initial gut microbiota composition in preterm infants. Besides, compared to term infants, premature infants often receive antibiotics to treat infections and probiotics to restore optimal gut microbiota. How GA, antibiotics, and probiotics modulate the microbiota’s core characteristics, gut resistome and mobilome, remains nascent. Methods - We analysed metagenomic data from a longitudinal observational study in six Norwegian neonatal intensive care units to describe the bacterial microbiota of infants of varying GA and receiving different treatments. The cohort consisted of probiotic-supplemented and antibiotic-exposed extremely preterm infants (n = 29), antibiotic-exposed very preterm (n = 25), antibiotic-unexposed very preterm (n = 8), and antibiotic-unexposed full-term (n = 10) infants. The stool samples were collected on days of life 7, 28, 120, and 365, and DNA extraction was followed by shotgun metagenome sequencing and bioinformatical analysis. Findings - The top predictors of microbiota maturation were hospitalisation length and GA. Probiotic administration rendered the gut microbiota and resistome of extremely preterm infants more alike to term infants on day 7 and ameliorated GA-driven loss of microbiota interconnectivity and stability. GA, hospitalisation, and both microbiota-modifying treatments (antibiotics and probiotics) contributed to an elevated carriage of mobile genetic elements in preterm infants compared to term controls. Finally, Escherichia coli was associated with the highest number of antibiotic-resistance genes, followed by Klebsiella pneumoniae and Klebsiella aerogenes. Interpretation - Prolonged hospitalisation, antibiotics, and probiotic intervention contribute to dynamic alterations in resistome and mobilome, gut microbiota characteristics relevant to infection risk. Funding - Odd-Berg Group, Northern Norway Regional Health Authority. |
format |
Article in Journal/Newspaper |
author |
Bargheet, Ahmed Klingenberg, Claus Andreas Esaiassen, Eirin Hjerde, Erik Cavanagh, Jorunn Pauline Bengtsson-Palme, Johan Pettersen, Veronika K. |
spellingShingle |
Bargheet, Ahmed Klingenberg, Claus Andreas Esaiassen, Eirin Hjerde, Erik Cavanagh, Jorunn Pauline Bengtsson-Palme, Johan Pettersen, Veronika K. Development of early life gut resistome and mobilome across gestational ages and microbiota-modifying treatments |
author_facet |
Bargheet, Ahmed Klingenberg, Claus Andreas Esaiassen, Eirin Hjerde, Erik Cavanagh, Jorunn Pauline Bengtsson-Palme, Johan Pettersen, Veronika K. |
author_sort |
Bargheet, Ahmed |
title |
Development of early life gut resistome and mobilome across gestational ages and microbiota-modifying treatments |
title_short |
Development of early life gut resistome and mobilome across gestational ages and microbiota-modifying treatments |
title_full |
Development of early life gut resistome and mobilome across gestational ages and microbiota-modifying treatments |
title_fullStr |
Development of early life gut resistome and mobilome across gestational ages and microbiota-modifying treatments |
title_full_unstemmed |
Development of early life gut resistome and mobilome across gestational ages and microbiota-modifying treatments |
title_sort |
development of early life gut resistome and mobilome across gestational ages and microbiota-modifying treatments |
publisher |
Elsevier |
publishDate |
2023 |
url |
https://hdl.handle.net/10037/30066 https://doi.org/10.1016/j.ebiom.2023.104613 |
geographic |
Norway |
geographic_facet |
Norway |
genre |
Northern Norway |
genre_facet |
Northern Norway |
op_relation |
EBioMedicine Sigma2: NN8021K Tromsø forskningsstiftelse: 18_CANS_AS Bargheet, Klingenberg, Esaiassen, Hjerde, Cavanagh, Bengtsson-Palme, Pettersen. Development of early life gut resistome and mobilome across gestational ages and microbiota-modifying treatments. EBioMedicine. 2023;92 FRIDAID 2151471 doi:10.1016/j.ebiom.2023.104613 2352-3964 https://hdl.handle.net/10037/30066 |
op_rights |
Attribution 4.0 International (CC BY 4.0) openAccess Copyright 2023 The Author(s) https://creativecommons.org/licenses/by/4.0 |
op_doi |
https://doi.org/10.1016/j.ebiom.2023.104613 |
container_title |
eBioMedicine |
container_volume |
92 |
container_start_page |
104613 |
_version_ |
1776202510832238592 |